Company: CERO
Filing Date: 2025-04-28
Form Type: 10-K/A
Source: 0001213900-25-036075
Chunk: 32

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-28
Form: 10-K/A
Chunk 32
---
00 per share. On February 14, 2024, upon consummation of the Business Combination, these options were assumed by us and converted into options to purchase shares in CERo at a conversion rate of 0.064452 underlying shares per legacy share and a strike price calculated as the legacy strike price divided by 0.064452. This resulted in the issuance of options to purchase 504 shares of common stock at a weighted average price of $436.00. As of October 1, 2024, the board of directors approved option awards to the executive officers for 2024, as set forth below:

| Name and Position                                               |     | Stock   
 Options |        |
| Chris Ehrlich, Chief Executive Officer and Chairman(1)          |     |         | 25,500 |
| Andrew “Al” Kucharchuk, Chief Financial Officer                 |     |         |  5,000 |
| Kristen Pierce, Ph.D., Chief Development Officer                |     |         |  2,659 |
| Brian G. Atwood, Former Chief Executive Officer and Chairman(2) |     |         |  5,080 |
| Charles R. Carter, Former Chief Financial Officer(3)            |     |         |      — |
| Daniel Corey, M.D., Former Chief Technology Officer(4)          |     |         |      — |

| (1) | Excludes 5,272 options granted under the 2024 Plan which were 
 forfeited on September 30, 2024.                              |

| (2) | Excludes 13,318 options granted under the 2024 Plan which were 
 forfeited on September 30, 2024.                               |

| (3) | Excludes 4,954 options granted under the 2024 Plan which were 
 forfeited on September 30, 2024.                              |

| (4) | Excludes 4,613 options granted under the 2024 Plan which were 
 forfeited on September 23, 2024.                              |

16 Equity Grant Timing Our compensation committee has generally granted equity awards on an annual basis and when it has determined necessary or appropriate for retention and recruitment, including following the successful completion of major corporate transactions or regulatory milestones. In addition, eligible employees, including our NEOs, may voluntarily enroll in our 2024 Employee Stock Purchase Plan, or ESPP, and receive an option to purchase shares at a discount using payroll deductions accumulated during